Boehringer Ingelheim Company Profile

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are seventy US patents protecting BOEHRINGER INGELHEIM drugs.

There are one thousand eight hundred and twenty-six patent family members on BOEHRINGER INGELHEIM drugs in sixty-three countries and two hundred and seventeen supplementary protection certificates in nineteen countries.

Summary for Boehringer Ingelheim

International Patents:	1826
US Patents:	70
Tradenames:	37
Ingredients:	29
NDAs:	48
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	9,486,526*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes	7,713,938*PED				Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes	8,545,884*PED				Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016		RX	Yes	No	9,949,998*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No

Expired US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	6,977,042
Boehringer Ingelheim	ALUPENT	metaproterenol sulfate	SOLUTION;INHALATION	018761-001	Jun 30, 1983	3,422,196
Boehringer Ingelheim	VIRAMUNE	nevirapine	SUSPENSION;ORAL	020933-001	Sep 11, 1998	5,366,972*PED
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850-002	Nov 10, 1998	8,003,679
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016	6,488,962

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	10 mg/5 mg and 25 mg/5 mg		2018-08-01
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Tablets	0.75 mg		2008-07-31
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg		2018-08-01
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01
	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg		2018-08-01
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12
	Tablets	10 mg and 25 mg		2018-08-01
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27
	Capsules	100 mg and 150 mg		2018-10-15
	Tablets	0.25 mg		2005-05-27
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Tablets	5 mg		2015-05-04
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26

International Patents for Boehringer Ingelheim Drugs

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	009663
Croatia	P20140645
South Korea	101052436
Spain	2669469
European Patent Office	1830843

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1830843	C300747	Netherlands		PRODUCT NAME: NINTEDANIB, OF EEN TAUTOMEER,; REGISTRATION NO/DATE: EU/1/14/979 20150115
2187879	1790019-2	Sweden		PRODUCT NAME: COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1146 20161115
1345910	6/2014	Austria		PRODUCT NAME: AFATINIB, DEREN TAUTOMERE, DEREN STEREOISOMERE UND DEREN SALZE, PHYSIOLOGISCH VERTRAEGLICHE SALZE MIT ANORGANISCHEN ODER ORGANISCHEN SAEUREN ODER BASEN, BEVORZUGT DEREN MALEATSALZE, VORZUGSWEISE DEREN DIMALEATSALZE; REGISTRATION NO/DATE: EU/1/13/879 20130925
0418716	05C0039	France		PRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009
1224170	C300725	Netherlands		PRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim